Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

Kühn, E W; Walz, G The Treatment of Autosomal Dominant Polycystic Kidney Disease Dtsch Arztebl Int 2015; 112(51-52): ; DOI: /arztebl

Date of download: 7/11/2016 From: Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Ann Intern Med. 2013;159(6):

© 2016 S. Karger AG, Basel. All rights reserved Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency.

November 3, 2012 N Engl J Med DOI: /NEJMoa

An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI: / Fig. 1. Occurrence of two.

Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998– DOI: / © 2008.

Ann Intern Med. 2013;159(6): doi: / Figure Legend:

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection:

Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Nat. Rev. Nephrol. doi: /nrneph

Thadhani et al. Am J Nephrol 2017;45:40-48 (DOI: / )

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Fan et al. Am J Nephrol 2017;45: (DOI: / )

Kuwabara et al. Am J Nephrol 2017;45: (DOI: / )

Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection:

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Bhandari et al. Am J Nephrol 2017;45: (DOI: / )

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology.

A Systematic Review and Meta-Analysis

Nat. Rev. Nephrol. doi: /nrneph

Thiazide-Associated Hyponatremia, Report of the Hyponatremia Registry: An Observational Multicenter International Study Burst et al. Am J Nephrol 2017;45:

Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

Robert W. Schrier, Kimberly K. McFann, Ann M. Johnson

Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease

Psychosocial Factors and 30-Day Hospital Readmission among Individuals Receiving Maintenance Dialysis: A Prospective Study Flythe et al. Am J Nephrol 2017;45:

Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection:

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:

Fig. 1. MAHALO clinical trial flowchart.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects Akizawa et.

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

J. Avouac, M.D., L. Gossec, M.D., M. Dougados, M.D.

Fig. 6-CO, p. 211.

Nat. Rev. Nephrol. doi: /nrneph

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Payan Schober et al. Am J Nephrol 2017;45: (DOI: / )

Reducing antibiotic use in influenza: challenges and rewards

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Copyright © 2013 Elsevier Inc. All rights reserved.

Targeting Immunity in End-Stage Renal Disease

Vitamin D in chronic kidney disease: is the jury in?

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

August Heidland, MD, Udo Bahner, MD, Spiros Vamvakas, MD

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Calcifications in autosomal dominant polycystic kidneys.

Role of glucocorticoids in acidosis

Volume 72, Issue 11, Pages (December 2007)

Overview of medical therapy for gastroesophageal disease

This comparative clinical trial of IV epoetin alfa-epbx versus epoetin alfa was a randomized, active-controlled, parallel-group, double-blind study including.

Genetic Features of Chinese Patients with Gitelman Syndrome:

Álvares et al. Am J Nephrol 2017;45: (DOI: / )

Darshi et al. Am J Nephrol 2016;44: (DOI: / )

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Extended Registration KS3

Presentation transcript:

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J Nephrol 2017;45:257-266 (DOI:10.1159/000456087) Table 1. Eligibility requirements for REPRISE

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J Nephrol 2017;45:257-266 (DOI:10.1159/000456087) Table 2. Study sites and number randomized

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J Nephrol 2017;45:257-266 (DOI:10.1159/000456087) Fig. 1. REPRISE study schematic. F/U, follow-up. * Can be extended up to an additional 8 weeks for subjects needing stabilization after changing other treatments.